Clinical trial NCT05395286: Innovation Labs to Enhance Collaboration
Official title: Controlled Evaluation of Innovation Labs for Enhancing Collaboration Among Early Career Scholars in the CTSA Network
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Collaboration Attitudes and Behavior
Lead sponsor: State University of New York at Buffalo
Sponsor class: OTHER
Collaborators: name: National Center for Advancing Translational Sciences (NCATS)
First posted: 2022-05-27
Enrollment: 94
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: We will conduct and evaluate the impact of two week-long Innovation Labs on collaboration attitudes and behavior among early career scholars. Applicants to each Innovation Lab will be screened and then randomized to either the Innovation Lab group or a control group.

Detailed description: Building on the science of team science and preliminary work at the Buffalo and Vanderbilt CTSAs, we propose to work with our industry partner Knowinnovation to implement, assess, and disseminate an innovative and promising method for stimulating and nurturing new transdisciplinary research teams across the CTSA Program consortium: Innovation Labs. We will focus on early career investigators, have well-developed expertise, and will benefit from developing transdisciplinary collaborations. This work will further advance the field by taking a strong translational science approach to identify and test "best practices". To accomplish this, we will critically evaluate the impact of Innovation Labs in two preliminary randomized controlled trials (RCTs). In collaboration with NCATs and broad input from the CTSA network, we will develop a clinical and translational research grand challenge focus for each Innovation Lab. A diverse applicant pool of early career investigators invited from every CTSA hub in the consortium will be reviewed, and top applicants will be randomized to a 5-day residential Innovation Lab or "treatment as usual" control group (n=25/group/RCT). Measures of process and outcome will be collected from the application phase through 12-month follow-up and aggregated across the two RCTs. Given the preliminary nature of the work and an emerging consensus regarding the science of team science, primary outcomes will be measures of the depth and breadth of participants collaborative networks and attitudes towards collaboration, which we predict will be enhanced in the Innovation Lab group compared to the treatment as usual control group. We will also gather initial data on the degree to which Innovation Labs result in increased transdisciplinary collaborative output, including grant proposals, publications, and presentations. The significance of this work is clear: We aim to advance clinical and translational science by critically evaluating a potential "best practice" method for catalyzing collaborations and enhancing innovative translational research, a core goal of the CTSA Program. Our initial RCTs target an important segment of the workforce and begin the process of dissemination across the CTSA network, setting the stage for much broader implementation and impact.

Eligibility criteria: Inclusion Criteria:

Completion of application and baseline assessment.

For randomization:

* Faculty at a NIH CTSA hub institution or regional partner.
* Early stage investigators (NIH-defined as "within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent)") who are emerging as independent scholars.
* Applications were reviewed for the above criteria and ranked by committee according to goodness of fit with the topic of the Innovation Lab, the quality and quantity of academic productivity and collaboration, and contribution to diversity of perspectives among Lab participants (e.g., biomedical and social/psychological, basic and applied). Top-ranked applicants were retained for randomization to the Innovation Lab group or control group.

All applicants (including 94 randomized ppts and 13 ppts who were not randomized) were encouraged to remain in the study and complete the follow-up assessments.

Primary outcomes:
measure: Change from Baseline MATRICx Benefits Scale
timeFrame: through study completion, an average of 15 months
measure: Change from Baseline MATRICx Threats Scale
timeFrame: through study completion, an average of 15 months
measure: Change from Baseline Transdisciplinary Orientation Scale
timeFrame: through study completion, an average of 15 months
measure: Change from Baseline Collaboration Network Size
timeFrame: through study completion, an average of 15 months
Secondary outcomes:
measure: Change from Baseline Grants Submitted
timeFrame: through study completion, an average of 15 months
measure: ILab met goal - new collab
timeFrame: 3 months
measure: ILab met goal - novel proposals
timeFrame: 3 months
measure: ILab - recommend
timeFrame: 3 months
measure: ILab - positive impact
timeFrame: 3 months
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: University at Buffalo
state: New York
Study officials:
References: